Eptifibatide
A hospital-administered peptide used during cardiac procedures. Not a wellness peptide.
This peptide is an FDA-approved drug product that can be legally prescribed by licensed clinicians.
The basics
- Generic Name
- eptifibatide (cyclic peptide antiplatelet)
- Brand Names
- Integrilin
- Regulatory Status
- Prescribed by Doctors
- Therapeutic Areas
- Cardiovascular
- Prescribing Specialties
- Cardiology
What it does
Eptifibatide is an FDA-approved medication that your doctor can prescribe. Cyclic heptapeptide that reversibly inhibits platelet aggregation by blocking the glycoprotein IIb/IIIa receptor, preventing fibrinogen binding between platelets.
How it's taken
Intravenous infusion (hospital setting only)
How people access it
Hospital-administered during cardiac procedures. Not a take-home medication.
What doctors prescribe it for
- Acute coronary syndrome (unstable angina/non-ST-elevation MI)
- Percutaneous coronary intervention (PCI)
Clinicians may prescribe FDA-approved drugs for off-label uses based on their clinical judgment. Off-label indications have not undergone the same FDA review process as the labeled uses listed above.
How to know it's legit
You can independently verify the FDA-approval status of Eptifibatide through these free, publicly available databases:
- DailyMed (dailymed.nlm.nih.gov) — Search for Integrilin to find the current FDA-approved labeling, including indications, dosing, warnings, and contraindications.
- Drugs@FDA (accessdata.fda.gov/scripts/cder/daf/) — Search to find the original approval letter, review documents, and approval history.
- FDA Orange Book (orangebook.fda.gov) — Search for therapeutic equivalence evaluations and patent/exclusivity information.
Common Questions
Yes. Eptifibatide (Integrilin) is an FDA-approved drug product. It has undergone rigorous review of safety, efficacy, and manufacturing quality by the FDA. It can be legally prescribed by licensed clinicians for its approved indications.
Eptifibatide is FDA-approved for: Acute coronary syndrome (unstable angina/non-ST-elevation MI); Percutaneous coronary intervention (PCI). Off-label use may be considered by clinicians on a case-by-case basis, but only the labeled indications have been reviewed and approved by the FDA.
You can verify the approval status of Eptifibatide through several official FDA resources: DailyMed (dailymed.nlm.nih.gov) for current labeling, Drugs@FDA (accessdata.fda.gov/scripts/cder/daf/) for approval history, and the FDA Orange Book for therapeutic equivalence information. These are free, publicly available databases.
Want to learn more?
Explore how Eptifibatide compares to other options, or dive deeper into how FDA approval works.
Explore All Peptides